YolTech Therapeutics
YolTech explicitly lists YOLT-401 for autoimmune disease as an in vivo CAR-T program with an undisclosed target. Its clinical gene-editing programs are separate; their stages and delivery details are not automatically assigned to YOLT-401.
Corporate information
- Company entity
- YolTech Therapeutics
- Headquarters / principal office
- ShanghaiSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2021 ↗
- Ownership / capital status
- PrivateSeries B (historical disclosure) ↗
- Official corporate reference
- https://yoltx.com/science/pipelines ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-09-11 · Series B · CNY >300 million ↗
Company reports more than CNY300 million; no exact amount is inferred from this lower bound.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
YolTech explicitly lists YOLT-401 for autoimmune disease as an in vivo CAR-T program with an undisclosed target. Its clinical gene-editing programs are separate; their stages and delivery details are not automatically assigned to YOLT-401.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- YolTech Therapeutics — official page checked November 4, 2026
- Company-managed LinkedIn profile — self-reported location
- Corporate ownership / financing disclosure